

Drug Monograph

Drug/Drug **Ingrezza® (valbenazine) capsule/ Vesicular Monoamine**
 Class: **Transporter 2 (VMAT2) Inhibitor**
 Prepared for: MO HealthNet
 Prepared by: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Ingrezza is now available in a 28-day initiation pack containing seven 40 mg capsules and twenty one 80 mg capsules.

Manufacturer: Distributed by: Neurocrine Biosciences, Inc. San Diego, CA 92130

Indications: Ingrezza is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia.

Costs: \$6,447.84 per 28 day titration pack of Ingrezza. Wholesale Acquisition Cost

Summary of Findings: The MO HealthNet Division recommends prior authorization status for this product.

Status Recommendation: Prior Authorization (PA) Required Open Access
 Fiscal Edit PDL

Type of PA Criteria: Increased Risk of ADE Preferred
 Appropriate Indications No PA Required

Prepared By: Jennifer Anderson PharmD
 Date: June 24, 2019